In last trading session, Protalix BioTherapeutics Inc. (AMEX:PLX) saw 0.34 million shares changing hands with its beta currently measuring 0.89. Company’s recent per share price level of $1.18 trading at -$0.04 or -3.28% at ring of the bell on the day assigns it a market valuation of $86.20M. That closing price of PLX’s stock is at a discount of -200.85% from its 52-week high price of $3.55 and is indicating a premium of 0.85% from its 52-week low price of $1.17. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.35 million shares which gives us an average trading volume of 338.87K if we extend that period to 3-months.
Protalix BioTherapeutics Inc. (AMEX:PLX) trade information
Upright in the red during last session for losing -3.28%, in the last five days PLX remained trading in the green while hitting it’s week-highest on Tuesday, 04/09/24 when the stock touched $1.18 price level, adding 12.59% to its value on the day. Protalix BioTherapeutics Inc.’s shares saw a change of -33.71% in year-to-date performance and have moved 0.85% in past 5-day. Protalix BioTherapeutics Inc. (AMEX:PLX) showed a performance of -22.37% in past 30-days. Number of shares sold short was 6.46 million shares which calculate 15.22 days to cover the short interests.
Protalix BioTherapeutics Inc. (PLX) estimates and forecasts
Statistics highlight that Protalix BioTherapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -23.87% of value to its shares in past 6 months, showing an annual growth rate of 66.67% while that of industry is 13.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 71.40% in the current quarter and calculating -109.50% decrease in the next quarter. This year revenue growth is estimated to rise 13.10% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $9.2 million for the same. And 1 analysts are in estimates of company making revenue of $8.9 million in the next quarter that will end on Jun 2024.
In 2024, company’s earnings growth rate is likely to be around 133.33% while estimates for its earnings growth in next 5 years are of 25.00%.
PLX Dividends
Protalix BioTherapeutics Inc. is more likely to be releasing its next quarterly report between May 02 and May 06 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Protalix BioTherapeutics Inc. (AMEX:PLX)’s Major holders
Insiders are in possession of 9.77% of company’s total shares while institution are holding 14.03 percent of that, with stock having share float percentage of 15.55%. Investors also watch the number of corporate investors in a company very closely, which is 14.03% institutions for Protalix BioTherapeutics Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at PLX for having 2.64 million shares of worth $5.28 million. And as of Jun 29, 2023, it was holding 3.69% of the company’s outstanding shares.
The second largest institutional holder is State Street Corporation, which was holding about 0.73 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 1.02% of outstanding shares, having a total worth of $1.46 million.
On the other hand, iShares Russell 2000 ETF and Fidelity Small Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 1.19 million shares of worth $2.25 million or 1.66% of the total outstanding shares. The later fund manager was in possession of 0.49 million shares on Jul 30, 2023, making its stake of worth around $0.79 million in the company or a holder of 0.69% of company’s stock.
